Neill E A, Chapple D J, Thompson C W
Br J Anaesth. 1983;55 Suppl 1:23S-25S.
Atracurium, a new competitive neuromuscular blocking agent, is broken down in the body by two mechanisms, Hofmann elimination and ester hydrolysis. Chemical breakdown by Hofmann elimination is rapid at physiological pH and temperature, whereas ester hydrolysis is enzyme-catalysed but by enzymes other than pseudocholinesterase. The products of these reactions have been shown to lack neuromuscular or cardiovascular activity at the concentrations occurring after therapeutic doses of atracurium. Studies with radiolabelled drug in anaesthetized cats have shown that atracurium and its metabolites are readily excreted in bile and urine. Plasma kinetics are unaltered if renal function is negated by bilateral ligation of all renal blood vessels. Preliminary studies have indicated that atracurium does not cross the placenta to a significant extent and that the drug can be used safety in Caesarean section.
阿曲库铵是一种新型竞争性神经肌肉阻滞剂,在体内通过两种机制分解,即霍夫曼消除和酯水解。在生理pH值和温度下,霍夫曼消除引起的化学分解很快,而酯水解是由酶催化的,但不是由假性胆碱酯酶催化,而是由其他酶催化。这些反应的产物在治疗剂量的阿曲库铵给药后所出现的浓度下,已显示缺乏神经肌肉或心血管活性。对麻醉猫进行的放射性标记药物研究表明,阿曲库铵及其代谢产物很容易经胆汁和尿液排出。如果通过双侧结扎所有肾血管使肾功能丧失,血浆动力学不会改变。初步研究表明,阿曲库铵不会大量穿过胎盘,该药物可在剖宫产中安全使用。